Suppr超能文献

三七(Panax notoginseng)注射剂治疗心绞痛。

Sanqi panax notoginseng injection for angina pectoris.

机构信息

Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.

出版信息

Evid Based Complement Alternat Med. 2014;2014:963208. doi: 10.1155/2014/963208. Epub 2014 Feb 16.

Abstract

OBJECTIVE

To evaluate the clinical curative effects of SPN injection on AP.

METHODS

Six databases were systematically searched including Cochrane Central, PubMed, EMBASE, CBM, Chinese National Knowledge Infrastructure (CNKI), and VIP to identify randomized controlled trials (RCTs). We assessed the quality of included studies, extracted valid data, and undertook meta-analysis following the steps of systematic review recommended by the Cochrane group.

RESULTS

Ten moderate-to-low quality randomized controlled trials involving 969 patients were included. There was no evidence that SPN alone had better or worse effects than conventional drugs on improving clinical symptoms (RR 1.09, 95% CI 0.85 to 1.39) and ECG (RR 1.17, 95% CI 0.84 to 1.63). However, there was an evidence that SPN combined with western medications was a better treatment option than conventional drugs alone in improving clinical symptoms (RR 1.28, 95% CI 1.19 to 1.33) and ECG (RR 1.27, 95% CI 1.12 to 1.45). No serious adverse effects were reported.

CONCLUSION

Compared with conventional treatment, SPN may show the potential of optimizing symptomatic outcomes. As a kind of alternative and complementary medicine, SPN may provide another choice for AP patients and further large-scale high-quality trials are needed to confirm this efficacy.

摘要

目的

评价参麦注射液治疗急性心肌梗死的临床疗效。

方法

系统检索 Cochrane 图书馆、PubMed、EMBASE、CBM、中国知网(CNKI)、维普数据库,收集参麦注射液治疗急性心肌梗死的随机对照试验,按照 Cochrane 系统评价方法评价纳入研究的质量并提取有效数据,采用 RevMan5.3 软件进行 Meta 分析。

结果

共纳入 10 项中低质量的随机对照试验,合计 969 例患者。结果显示,参麦注射液与常规西药比较,在改善临床症状[RR=1.09,95%CI(0.85,1.39)]和心电图[RR=1.17,95%CI(0.84,1.63)]方面疗效相当;而参麦注射液联合常规西药较常规西药比较,能更有效改善临床症状[RR=1.28,95%CI(1.19,1.33)]和心电图[RR=1.27,95%CI(1.12,1.45)]。未见严重不良反应报道。

结论

与常规西药比较,参麦注射液可能具有优化症状结局的潜力。作为一种替代和补充医学,参麦注射液可能为急性心肌梗死患者提供另一种选择,还需要进一步开展大规模高质量的临床试验来验证其疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e611/3947822/6a31fb506579/ECAM2014-963208.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验